Point-of-Care Adipose-derived Cells for Hair Growth

Status Completed

Clinical Trial Summary

Androgenetic alopecia (AGA) is the most common form of hair loss and affects 50% and 23% of Caucasian men and women, respectively, over the age of 50. The percentage of men and women affected over the age of 70 increases to 80% and 60% of Caucasian men and women, respectively. Although alopecia is considered a minor dermatologic condition, it is seen as a serious condition with major life consequences by those with alopecia and has been associated with increased incidence of myocardial infarction, hypertension and hypercholesterolaemia. Androgenetic alopecia is associated with feelings of anxiety, depression and various personality disorders among men and women due to physical appearance. Depression, anxiety, aggressiveness, impaired quality of life and social inadequacy have been documented. The presence of alopecia in women is particularly stressful.

ADSCs (Adipose Derived Stromal Cells), also called Stromal Vascular Fraction (SVF) cells, include regenerative cell populations derived from adipose tissue and thus are potentially important to multiple disease processes and therapeutic applications for the repair and regeneration of acute and chronically damaged tissues. It has been postulated that SVF cells may promote hair regeneration by increasing the hair-inducing ability of dermal papillae (DP) cells.

The general objective of this study is to conduct a safety and feasibility study of a single injection of autologous adipose-derived SVF cells for the treatment of alopecia.

Clinical Trial Description

This is a prospective, non-randomized, non-blinded, interventional, consecutive series, single site study to determine initial safety and feasibility of a single injection of autologous adipose-derived SVF cells for the treatment of alopecia.

Up to 8 subjects who have been diagnosed with androgenetic alopecia will be asked to participate. Before the procedure the density (number of hairs per square centimeter) and thickness (mm) of the hair will be measured and compared to the same measurements after the procedure. All adverse events will be recorded and evaluated for severity.

Subjects will be asked to come into the office on the following days: pre-procedure visit, 24 hours post procedure visit, 6 weeks post procedure visit, 3 months post procedure visit and 6 months post procedure visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02729415
Study type	Interventional
Source	University of Florida
Contact
Status	Completed
Phase	N/A
Start date	October 2016
Completion date	January 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02591355` - Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment	N/A
Withdrawn	`NCT03852992` - Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia	Phase 2
Recruiting	`NCT06239207` - Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia	Phase 2
Completed	`NCT04945226` - A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001	Phase 1/Phase 2
Completed	`NCT01437163` - Treatment of Androgenetic Alopecia in Males and Females	N/A
Completed	`NCT01548066` - The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss	Phase 2
Completed	`NCT01226459` - Clinical Trial in Females for Female Pattern Hair Loss	Phase 3
Recruiting	`NCT06118866` - A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia	Phase 2
Completed	`NCT06149221` - Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss	N/A
Withdrawn	`NCT04882969` - Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia	N/A
Completed	`NCT01231607` - Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia	Phase 3
Completed	`NCT04446429` - Anti-Androgen Treatment for COVID-19	N/A
Completed	`NCT02279823` - A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia	Phase 2
Not yet recruiting	`NCT01227031` - Pharmacogenomic Study of Androgenetic Alopecia	N/A
Completed	`NCT00981461` - Treatment of Androgenetic Alopecia in Females, 9 Beam	N/A
Completed	`NCT01451021` - A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss	Phase 2
Completed	`NCT00151515` - A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss	Phase 3
Completed	`NCT03694067` - Androgenetic Alopecia and the JAK-STAT Pathway
Completed	`NCT03689452` - The Effect of Platelet Rich Plasma on Non-scarring Alopecia	N/A
Completed	`NCT03753113` - Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Point-of-Care Adipose-derived Cells for Hair Growth — ASVF-2016

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms